The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...